CA2550844A1 - Nicotinic acetylcholine receptor ligands - Google Patents

Nicotinic acetylcholine receptor ligands Download PDF

Info

Publication number
CA2550844A1
CA2550844A1 CA002550844A CA2550844A CA2550844A1 CA 2550844 A1 CA2550844 A1 CA 2550844A1 CA 002550844 A CA002550844 A CA 002550844A CA 2550844 A CA2550844 A CA 2550844A CA 2550844 A1 CA2550844 A1 CA 2550844A1
Authority
CA
Canada
Prior art keywords
disease
atoms
sulfur
oxygen
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002550844A
Other languages
English (en)
French (fr)
Inventor
Glen Ernst
Robert Jacobs
Eifion Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2550844A1 publication Critical patent/CA2550844A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002550844A 2003-12-22 2004-12-20 Nicotinic acetylcholine receptor ligands Abandoned CA2550844A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53171203P 2003-12-22 2003-12-22
US60/531,712 2003-12-22
PCT/SE2004/001940 WO2005061494A1 (en) 2003-12-22 2004-12-20 Nicotinic acetylcholine receptor ligands

Publications (1)

Publication Number Publication Date
CA2550844A1 true CA2550844A1 (en) 2005-07-07

Family

ID=34710246

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002550844A Abandoned CA2550844A1 (en) 2003-12-22 2004-12-20 Nicotinic acetylcholine receptor ligands

Country Status (14)

Country Link
US (1) US20070270458A1 (cg-RX-API-DMAC7.html)
EP (1) EP1699786A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007515478A (cg-RX-API-DMAC7.html)
KR (1) KR20060125812A (cg-RX-API-DMAC7.html)
CN (1) CN1914201A (cg-RX-API-DMAC7.html)
AU (1) AU2004303737A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0417927A (cg-RX-API-DMAC7.html)
CA (1) CA2550844A1 (cg-RX-API-DMAC7.html)
IL (1) IL176071A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06007026A (cg-RX-API-DMAC7.html)
NO (1) NO20063356L (cg-RX-API-DMAC7.html)
SG (1) SG149052A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005061494A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200605074B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2582339C2 (ru) 2010-05-27 2016-04-27 Таргасепт, Инк. Неконкурентные антагонисты никотиновых рецепторов
EP2593447B1 (de) 2010-07-15 2016-08-17 Bayer Intellectual Property GmbH 3-pyridyl-heteroarylcarboxamidverbindungen als schädlingsbekämpfungsmittel
CA3169697A1 (en) * 2020-02-28 2021-09-02 Dominic Reynolds Thiophenyl derivatives useful for modulating nucleic acid splicing

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2529548A1 (fr) * 1982-07-02 1984-01-06 Delalande Sa Nouveaux derives de l'amino-3 quinuclidine, leur procede et leur application en therapeutique
EP0287196B1 (en) * 1987-02-18 1994-11-23 Beecham Group Plc Indole derivatives, process for their preparation and pharmaceutical compositions containing them
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
WO2002015662A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
WO2002017358A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
JP2004506734A (ja) * 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
DE10156719A1 (de) * 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide

Also Published As

Publication number Publication date
ZA200605074B (en) 2007-05-30
SG149052A1 (en) 2009-01-29
WO2005061494A1 (en) 2005-07-07
US20070270458A1 (en) 2007-11-22
MXPA06007026A (es) 2006-08-31
KR20060125812A (ko) 2006-12-06
AU2004303737A1 (en) 2005-07-07
BRPI0417927A (pt) 2007-04-17
EP1699786A1 (en) 2006-09-13
IL176071A0 (en) 2006-10-05
NO20063356L (no) 2006-09-21
JP2007515478A (ja) 2007-06-14
CN1914201A (zh) 2007-02-14

Similar Documents

Publication Publication Date Title
AU784400B2 (en) New use and novel N-azabicyclo-amide derivatives
US7566727B2 (en) 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydro-isoindole-1-one/5,6-dihydro-furo[2,3-c] pyrrol-4-one derivative ligands for alpha 7 nicotinic acetylcholine receptor
SK9932001A3 (en) Novel aralkyl amines of spirofuropyridines useful in therapy
EP2668186B1 (en) Pharmaceutical composition comprising pyridone derivatives
WO2004016616A1 (en) Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists.
CA2550655A1 (en) Nicotinic acetylcholine receptor ligands
CA2550847A1 (en) Nicotinic acetylcholine receptor ligands
US20070270458A1 (en) Nicotinic Acetylcholine Receptor Ligands
US7384954B2 (en) 4-substituted imidazoles
EP1673372B1 (en) Non-amide nonanes
CA2546093A1 (en) 5-substituted imidazoles
MXPA06011725A (en) Novel 2-(1-aza-bicyclo [2.2.2]oct-3-yl) -2, 3-dihydroisoindol -l-one/5, 6-dihydro-furo[2, 3-c]pyrrol -4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor
MXPA06005416A (en) 4-substituted imidazoles

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20101220